← FDA DRUG APPROVALS

FDA ANDA · ANDA091246

OXACILLIN SODIUM

Sponsor: SAGENT PHARMS

APPLICATION
ANDA091246
TYPE
ANDA
ORIGINAL APPROVAL
2012-03-30
LATEST ACTION
2016-04-04
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

OXACILLIN SODIUMDiscontinued
OXACILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
OXACILLIN SODIUMDiscontinued
OXACILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2016-04-04Labeling · Supplement 1 · standardAP
2012-03-30Original — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →